Stat5: from breast development to cancer prognosis, prediction, and progression.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed.

1. DNA methylation-mediated silencing of STAT5A drives breast cancer metastasis via dual regulation of EMT and immunosuppressive microenvironment.Oncogene · 2026
   Article
2. Bioprinting and Organ-on-Chip Applications Towards Personalized Medicine for Bone Diseases.Stem cell reviews and reports · 2017
   Review
3. The combination of methylsulfonylmethane and tamoxifen inhibits the Jak2/STAT5b pathway and synergistically inhibits tumor growth and metastasis in ER-positive breast cancer xenografts.BMC cancer · 2015
   Article
4. STAT3 genetic variant, alone and in combination with STAT5b polymorphism, contributes to breast cancer risk and clinical outcomes.Medical oncology (Northwood, London, England) · 2015
   Article
5. Cucurbitacin-I inhibits Aurora kinase A, Aurora kinase B and survivin, induces defects in cell cycle progression and promotes ABT-737-induced cell death in a caspase-independent manner in malignant human glioma cells.Cancer biology & therapy · 2015
   Article
6. Exome analysis reveals differentially mutated gene signatures of stage, grade and subtype in breast cancers.PloS one · 2015
   Article
7. STAT3 and STAT5b polymorphism contributes to breast cancer risk and clinical outcomes.International journal of clinical and experimental pathology · 2015
   Article
8. Enhanced T cell lymphoma in NOD.Stat5b transgenic mice is caused by hyperactivation of Stat5b in CD8+ thymocytes.PloS one · 2013
   Article
9. Is there any role for new prognostic markers in breast cancer?Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2012
   Review
10. Hwanggeumchal sorghum induces cell cycle arrest, and suppresses tumor growth and metastasis through Jak2/STAT pathways in breast cancer xenografts.PloS one · 2012
    Article
11. Methylsulfonylmethane suppresses breast cancer growth by down-regulating STAT3 and STAT5b pathways.PloS one · 2012
    Article
12. Reversal of aberrant cancer methylome and transcriptome upon direct reprogramming of lung cancer cells.Scientific reports · 2012
    Article

Corrections and comments

• Comment on
  Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure.2011

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as